Targeted FGFR Blockade for the Treatment of Tumor-Induced Osteomalacia (original) (raw)
Tumor-induced osteomalacia due to a recurrent mesenchymal tumor overexpressing several growth factor receptors
John Yovos, S. Tournis
Endocrinology, Diabetes & Metabolism Case Reports, 2015
View PDFchevron_right
FGF23 Producing Mesenchymal Tumor
Waldemar Misiorowski
Case Reports in Endocrinology, 2014
View PDFchevron_right
Targeting fibroblast growth factor receptor 1 for treatment of soft-tissue sarcoma
Matthias Scheffler
View PDFchevron_right
Hyperphosphatemic tumoral calcinosis caused by FGF23 compound heterozygous mutations: what are the therapeutic options for a better control of phosphatemia?
Frédérique Dijoud
Pediatric Nephrology, 2018
View PDFchevron_right
Regulation of osteosarcoma cell lung metastasis by the c-Fos/AP-1 target FGFR1
Isabelle Miletich
Oncogene, 2015
View PDFchevron_right
FGF23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting
anurag gupta
Journal of Clinical Investigation, 2003
View PDFchevron_right
FGFR Fusions in Cancer: From Diagnostic Approaches to Therapeutic Intervention
Francesco Izzo
International Journal of Molecular Sciences
View PDFchevron_right
Tumor-induced osteomalacia
Pablo Florenzano
Bone Reports, 2017
View PDFchevron_right
FGFR a promising druggable target in cancer: Molecular biology and new drugs
Peter van Dam
Critical reviews in oncology/hematology, 2017
View PDFchevron_right
Pan-FGFR Inhibition Leads to Blockade of FGF23 Signaling, Soft Tissue Mineralization, and Cardiovascular Dysfunction
Timothy Nichols
Toxicological Sciences, 2013
View PDFchevron_right
Sensitivity of Fibroblast Growth Factor 23 Measurements in Tumor-Induced Osteomalacia
Munro Peacock
The Journal of Clinical Endocrinology & Metabolism, 2006
View PDFchevron_right
Targeting the fibroblast growth factor receptor family in cancer
Shereen Rafee
Cancer Treatment Reviews, 2016
View PDFchevron_right
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
Somesh Choudhury
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017
View PDFchevron_right
Protein Tyrosine Phosphatase Receptor Type G (PTPRG) Controls Fibroblast Growth Factor Receptor (FGFR) 1 Activity and Influences Sensitivity to FGFR Kinase Inhibitors
Antoni Wiedlocha
Molecular & Cellular Proteomics, 2018
View PDFchevron_right
Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary
Olivier Déas
View PDFchevron_right
Targeting mutant fibroblast growth factor receptors in cancer
Pamela Pollock
Trends in molecular medicine, 2011
View PDFchevron_right
Fibroblast Growth Factor-23 Secreting Tumour Induced Osteomalacia
terry diamond
Austin Journal of Orthopedics & Rheumatology, 2021
View PDFchevron_right
The phosphatase PTPRG controls FGFR1 activity and influences sensitivity to FGFR kinase inhibitors
Antoni Wiedlocha
2017
View PDFchevron_right
De-regulated FGF receptors as therapeutic targets in cancer
Simon J Cook
Pharmacology & Therapeutics, 2010
View PDFchevron_right
Tumor targeting through fibroblast growth factor receptors
Douglas Lappi
Seminars in Cancer Biology, 1995
View PDFchevron_right
Fibroblast growth factors and their receptors in cancer
Kaisa Haglund
Biochemical Journal, 2011
View PDFchevron_right
Blocking the FGF/FGFR system as a “two-compartment” antiangiogenic/antitumor approach in cancer therapy
Marco Rusnati
Pharmacological Research, 2016
View PDFchevron_right
The hypoxia-inducible factor-1α activates ectopic production of fibroblast growth factor 23 in tumor-induced osteomalacia
Xiaobin Han
Bone research, 2016
View PDFchevron_right
Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers
Chee-Onn Leong
Apoptosis, 2013
View PDFchevron_right
Inhibition of FGF/FGFR autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039/GSK3052230
Hasan Alsaid
Oncotarget, 2016
View PDFchevron_right
Fibroblast growth factor family aberrations in cancers: clinical and molecular characteristics
Richard Schwab
Cell Cycle, 2015
View PDFchevron_right
Utility of Multimodality Approach Including Systemic FGF23 Venous Sampling in Localizing Phosphaturic Mesenchymal Tumors
Yoshitomo Hoshino
Journal of the Endocrine Society
View PDFchevron_right
Biological Significance and Targeting of the FGFR Axis in Cancer
Athina-Myrto Chioni
Cancers
View PDFchevron_right
Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapies
Poonam Nagpal
Oncotarget, 2016
View PDFchevron_right
Dialysis as a Treatment Option for a Patient With Normal Kidney Function and Familial Tumoral Calcinosis Due to a Compound Heterozygous FGF23 Mutation
Rosilene Elias
American journal of kidney diseases : the official journal of the National Kidney Foundation, 2018
View PDFchevron_right